NCT03219957

Study of AT-527 in Healthy and HCV-Infected Subjects

A Phase I Study Assessing Single and Multiple Doses of AT-527 in Healthy and HCV-Infected Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 88 (actual)
• Sponsor: Atea Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study has multiple parts. It will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 in healthy subjects and subjects infected with hepatitis C virus (HCV). In addition, the study will assess the antiviral activity of AT-527 in subjects infected with HCV.

Conditions

• Chronic Hepatitis C
• Hepatitis C
• Hepatitis C, Chronic

Interventions

Type	Name	Description
DRUG	AT-527	Ascending doses of AT-527 administered orally.
OTHER	Placebo Comparator	Matching placebo

Timeline

• Start date: 2017-07-06
• Primary completion: 2018-06-20
• Completion: 2018-06-20
• First posted: 2017-07-18
• Last updated: 2020-02-18

Locations

2 sites across 2 countries: Belgium, Moldova